The Lundquist Institute
Kevin W. is an accomplished financial executive with extensive experience in various leadership roles within the healthcare, biopharma, and financial services sectors. Currently serving as Chief Financial Officer at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Kevin previously held CFO positions at Saban Community Clinic and Buddhist Tzu Chi Medical Foundation. Notably, Kevin established Bold Therapeutics Inc. as its first CFO, contributing to its governance and investor outreach efforts. With a background that includes co-founding Enliven Financial and advising on corporate finance at Ascendo Financial, Kevin has a proven track record in strategic financial management, capital raising, and organizational leadership. Kevin earned a Master of Science in Management, Banking and Financial Management from New England College and a BGS in Applied Sciences from Simon Fraser University.
This person is not in any teams
This person is not in any offices
The Lundquist Institute
The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, The Lundquist Institute is poised to serve as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous orphan diseases, and is responsible for three FDA-approved drugs including the first approved treatment for sickle cell disease in 20 years.